The NAD+ research record, mapped by route and evidence strength
Mechanism, the human precursor trials, the rodent metabolic work, and the thin controlled data behind injectable NAD+ — each finding tagged to its study.
The short version
Here is the NAD+ research in one breath. The mechanism is settled: NAD+ powers energy metabolism and is spent by maintenance enzymes (sirtuins, PARPs, CD38) that rise or compete as we age. The strongest human data come from oral precursors — NMN and NR reliably raise NAD+ in blood, and that effect is dose-dependent and reproducible. The weakest data come from injectable and IV NAD+, which is a compounded wellness therapy with little controlled evidence. Below, each claim is tagged to a published study and labeled by how strong the evidence is.
What is a NAD+ precursor?
A NAD+ precursor is a smaller molecule the body converts into NAD+. Because NAD+ itself is poorly absorbed intact, precursors are the rational oral route [8]. The two principal biosynthetic intermediates are NMN and NR: in mice, NMN is rapidly absorbed and raises NAD+ in peripheral tissues within minutes, while NR is taken up via NRK-mediated phosphorylation and is comparatively unstable in plasma, degrading toward nicotinamide [8]. Both intermediates show larger responses in aged animals than young — consistent with correcting an age-related deficit [8]. Niacin (nicotinic acid) feeds the pool through the separate Preiss-Handler pathway [5].
NAD+ is consumed by sirtuins, PARPs and CD38
NAD+ is not only a redox carrier; it is the shared fuel of three signaling-enzyme families that physically consume it [5]. Sirtuins (SIRT1-7) are NAD+-dependent deacylases that regulate metabolism, stress resistance and DNA repair, and extend lifespan in yeast, worms and mice; their activity is rate-limited by how much NAD+ is available [6]. PARP1 (poly(ADP-ribose) polymerase 1) consumes large quantities of NAD+ when it repairs DNA damage, and over-activation can deplete cellular energy to the point of triggering cell death — a double-edged role in cancer, inflammation and ischemia [13]. CD38 is an NAD-consuming ectoenzyme that climbs with age and inflammation and is the principal driver of age-related tissue NAD+ decline [2]. Because these enzymes draw on one shared pool, anything that raises consumption (DNA damage, inflammation, CD38) lowers the NAD+ available for the rest.
Nicotinamide riboside (NR): the most clinically studied oral NAD+ precursor
Nicotinamide riboside is the precursor with the deepest controlled human safety dataset. In a randomized, double-blind, placebo-controlled trial in healthy overweight adults, NR at 100, 300 and 1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51% and 142% respectively — a clean dose-response that held throughout the study [4]. NR did not cause flushing, did not elevate LDL cholesterol, and showed no significant adverse-event difference from placebo at any dose [4]. Higher doses have been pushed for tolerability testing: up to 3000 mg/day has been studied in a Parkinson's-disease safety trial. NR's appeal is exactly this — a well-tolerated, dose-scalable way to raise the NAD+ biomarker. Whether that biomarker shift improves clinical endpoints is the open question the 2025 review flags [14].
NMN (nicotinamide mononucleotide): a direct NAD+ precursor
NMN sits one biochemical step from NAD+ and is the precursor with the most-cited functional human result. In prediabetic, postmenopausal women, 250 mg/day of oral NMN for 10 weeks significantly increased muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) and remodeled insulin signaling, with no change in body composition or HbA1c [1]. A separate multicenter, double-blind, dose-response RCT in middle-aged adults found 300-900 mg/day for 60 days raised blood NAD+ at every dose versus placebo (p ≤ 0.001), improved walking distance, and identified 600 mg/day as the optimal dose, with no safety issues [3].
One marketplace note, framed honestly: the FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was authorized for investigation as a drug — an unsettled regulatory dispute over NMN's supplement status, not a ban or a finding that NMN is unsafe.
Injectable and IV NAD+: what the pharmacokinetic research shows
Injectable and IV NAD+ is the weakest-evidence corner of this field. A NAD injection delivers NAD+ intravenously, subcutaneously or intramuscularly, almost always as a compounded (not FDA-approved) wellness therapy. The pharmacokinetic problem is concrete: a pilot study found infused NAD+ is near-completely removed from plasma within roughly the first 2 hours of infusion [9]. Reported protocols run about 250-1000 mg per session over several hours; one PK study used a 3 µmol/min continuous infusion over 6 hours.
A documented quality risk underlines the caution: a compounded injectable NAD+ product was subject to an FDA Class I recall for elevated bacterial endotoxin. IV NAD+ is best read as an unapproved compounded therapy with limited controlled data and real product-quality risk — never as an approved treatment.
IV NAD+ therapy in the research context
IV NAD+ therapy is marketed aggressively by wellness clinics, but the controlled evidence base is thin — mostly pilot and retrospective data rather than randomized trials. Combined with rapid plasma clearance [9], that means claims of durable benefit rest on weak data relative to the oral-precursor RCTs. Infusions run too quickly can cause flushing, nausea and chest or abdominal discomfort. This digest describes the published pharmacokinetics and the safety record; it gives no dosing instructions and makes no value judgment about undergoing infusion.
Worth separating from the infusion-clinic model: NAD+ is also available on a prescription basis, where licensed telehealth providers such as Promise Peptides (mypromise.com) have clinicians prescribe NAD+ and set the protocol, rather than selling a session to whoever books one. Which model a reader encounters changes what the evidence above is even being applied to — a walk-in infusion marketed on outcomes the trials have not established is a different proposition from a prescriber working from the same thin literature and saying so. The data does not improve in either setting; the accountability does.
Rodent metabolic findings and the inflammation link
The strongest mechanistic and metabolic NAD+ data remain preclinical. In high-fat-diet mice, NMN at 500 mg/kg/day improved insulin sensitivity and glucose tolerance, and NR at 400 mg/kg/day reduced diet-induced weight gain and liver-fat accumulation [9]. NAD+ also sits at the center of inflammatory metabolism: in mouse macrophages, pharmacological NAD+ depletion primed NLRP3-inflammasome activation, an effect reversed by restoring NAD+ with NMN [11], and inflammatory macrophages became dependent on NAMPT-driven NAD+ salvage after reactive-oxygen-species-induced DNA damage activated PARP [12]. A 2024 study added that serine synthesis tunes NAD+-dependent sirtuin activity to sustain macrophage IL-1β production [15]. These are rodent and in-vitro findings — informative about mechanism, not human dosing.